Search results for "Mace"

showing 10 items of 4713 documents

SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL SMALL MOLECULES AS PROMISING ALTERNATIVE AGENTS TO COUNTERACT DRUG RESISTANCE IN CANCER AND MICROBIAL IN…

2022

Il cancro rimane un grave problema di salute pubblica, rappresentando la seconda principale causa di morte in tutto il mondo. Tra le diverse tipologie di tumori, l'adenocarcinoma duttale pancreatico (PDAC) è una delle forme più letali nell'uomo, a causa della diagnosi tardiva e delle limitate possibilità di trattamento. Pertanto, lo studio di nuove strategie terapeutiche per i pazienti affetti da PDAC è altamente necessario. Allo stesso modo, il mesotelioma rappresenta una malattia rara ma aggressiva, difficile da diagnosticare per il lungo periodo di latenza prima dei segni clinici. Gli approcci terapeutici standard includono la chirurgia, la chemioterapia e la radioterapia. Tuttavia, la s…

CDK1Antibiofilm activityGSK3βMesothelioma ImidazothiadiazolePancreatic cancer124-OxadiazoleSettore CHIM/08 - Chimica Farmaceutica
researchProduct

ANALISI CHIMICO-TOSSICOLOGICA E CHEMIOMETRICA DI SEDIMENTI MARINO COSTIERI SICILIANI

2011

CHEMIOMETRICACHIMICO-TOSSICOLOGICASettore CHIM/08 - Chimica Farmaceutica
researchProduct

SYNTHETIC AND BIOLOGICAL EVALUATION OF SOME NEW 2-CINNAMAMIDOBENZAMIDES AS POTENTIAL ANTAGONIST OF THE HDM2-P53 PROTEIN-PROTEIN INTERACTIONS

2008

CINNAMAMMIDOBENZAMIDES ANTIPROLIFERATIVE ACTIVITYSettore CHIM/08 - Chimica Farmaceutica
researchProduct

Studio del ruolo delle mutazioni “gatekeeper” V654A e T670I di c-kit kinase nell’interazione con inibitori attraverso un approccio misto Dinamica Mol…

2012

La sovraespressione del proto-oncogene c-kit è stata riscontrata nelle cellule ematopoietiche, nel cancro a piccole cellule del polmone e nei tumori stromali gastrointestinali1-3. L’importanza clinica dell’espressione di c-kit nei tumori ha indirizzato la ricerca verso inibitori di questa tirosina chinasi. Imatinib (Gleevec®) (in figura) è stato il primo farmaco utilizzato in terapia, ma la comparsa di mutazioni su c-kit ha portato ad una riduzione dell’efficacia o a completa resistenza a questo trattamento. In alternativa, altri composti si sono mostrati attivi anche nei confronti dei mutanti come ad esempio Sunitinib (Sutent®)4, ma la necessità di nuovi e più efficaci inibitori contro i m…

CKIT MUTAZIONI INDUCED-FIT DOCKINGSettore CHIM/08 - Chimica Farmaceutica
researchProduct

Aminoacidic derivatives as novel CNS-targeted neurotherapeutics

2012

Drug delivery to the CNS is subject to the permeability limitations imposed by the BBB that regulates movements of actives in and out of the brain. During the drug discovery phase a key aspect could be the selection of the compounds properties crucial for brain penetration. Novel CNS-targeted neurotherapeutics should possess the optimal characteristics that allow passive diffusion through the BBB via the transcellular route, or have the structural features necessary to serve as a substrate for one of the endogenous transport systems of the BBB. An attractive and rewarding chemistry-based strategy, employed to increase the CNS transport of poorly penetrating therapeutic agents, is the transi…

CNS prodrugsSettore CHIM/09 - Farmaceutico Tecnologico Applicativo
researchProduct

Photoreduction of carbon dioxide to formic acid in aqueous suspension: a comparison between phthalocyanine/TiO2 and porphyrin/TiO2 catalysed processes

2014

Composite materials prepared by loading polycrystalline TiO2 powders with lipophilic highly branched Cu(II)- and metal-free phthalocyanines or porphyrins, which have been used in the past as photocatalysts for photodegradative processes, have been successfully tested for the efficient photoreduction of carbon dioxide in aqueous suspension affording significant amounts of formic acid. The results indicated that the presence of the sensitizers is beneficial for the photoactivity, confirming the important role of Cu(II) co-ordinated in the middle of the macrocycles. A comparison between Cu(II) phthalocyanines and Cu(II) porphyrins indicated that the Cu(II)- phthalocyanine sensitizer was more e…

CO<sub>2</sub>IndolesPorphyrinsFormatesFormic acidPharmaceutical Sciencechemistry.chemical_elementIsoindolesphthalocyaninesPhotochemistryCatalysisArticleGas Chromatography-Mass SpectrometryAnalytical ChemistryCatalysisCatalysilcsh:QD241-441Porphyrinchemistry.chemical_compoundPhotochemical Processelcsh:Organic chemistryDrug Discoveryphoto-reductionTiO2Physical and Theoretical ChemistryTitaniumOrganic ChemistryWaterphthalocyanines/porphyrinsCarbon DioxideHydrogen-Ion ConcentrationPhotochemical ProcessesFormateAqueous suspensionPorphyrinheterogeneous photocatalysischemistryChemistry (miscellaneous)IndoleCarbon dioxidePhthalocyanineMolecular MedicineCO2Spectrophotometry UltravioletCrystalliteTiO<sub>2</sub>Oxidation-ReductionTitanium
researchProduct

Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pande…

2020

Background Starting December 2019, mankind faced an unprecedented enemy, the COVID-19 virus. The world convened in international efforts, experiences and technologies in order to fight the emerging pandemic. Isolation, hygiene measure, diagnosis, and treatment are the most efficient ways of prevention and intervention nowadays. The health organizations and global care systems screened the available resources and offered recommendations of approved and proposed medications. However, the search for a specific selective therapy or vaccine against COVID-19 remains a challenge. Methods A literature search was performed for the screening of natural and derived bio-active compounds which showed po…

COVID-19 VaccinesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Drug Evaluation PreclinicalPharmaceutical ScienceAntiviral AgentsArticle03 medical and health scienceschemistry.chemical_compoundClinical trials0302 clinical medicineTocilizumabChloroquineDrug DiscoveryPandemicmedicineHumansAntiviralPandemics030304 developmental biologyPharmacologyBiological ProductsClinical Trials as TopicNatural products0303 health sciencesProtectionMolecular StructureTraditional medicineSARS-CoV-2business.industryCOVID-19LycorineFingolimodCOVID-19 Drug TreatmentClinical trialConessineComplementary and alternative medicinechemistry030220 oncology & carcinogenesisMolecular MedicinePatentPlant Preparationsbusinessmedicine.drugPhytomedicine
researchProduct

Higher Incidence of Cancer Therapy-Related Cardiac Dysfunction in the COVID-19 Era: A Single Cardio-Oncology Center Experience

2023

Aim: COVID-19 pandemic had a big impact on our life, it has revolutionized the practice of cardiology and the organization of hospital and outpatient activities. Thus the aim of our study was to assess the impact of the COVID-19 pandemic on the development of cancer therapy-related cardiac dysfunction (CTRCD). Methods and results: A single center retrospective study was carried out evaluating 96 cancer patients treated with anthracyclines and admitted to our Cardio-Oncology unit from June to August 2019 and 60 patients from June to August 2021. The incidence of CTRCD was assessed performing an echocardiogram at the time of the enrollment. We found a significantly higher incidence of CTRCD i…

COVID-19 CTRCD cardio-oncology cardiotoxicity pandemiccardio-oncology; cardiotoxicity; COVID-19; pandemic; CTRCDPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsJournal of Cardiovascular Development and Disease; Volume 10; Issue 1; Pages: 23
researchProduct

4,5,6,9-TETRAHYDROPYRROLO[2',3'-3,4]CYCLOEPTA[1,2-d]ISOSSAZOLE, PROCESS FOR THEIR PRODUCTION AND THEIR USES AS ANTITUMOR AGENTS

2016

The present invention concerns the synthesis of compounds bearing the PYRROLO[2',3'-3,4]CYCLOEPTA[1,2-d]ISOSSAZOLE structure, and their use for the treatment of pathologies having hyperproliferative features included those having neoplastic nature.

CYCLOEPTAISOSSAZOLE ANTITUMOR AGENTSSettore CHIM/08 - Chimica Farmaceutica
researchProduct

A systematic review and combined analysis of therapeutic drug monitoring studies for longacting risperidone

2017

Introduction: This systematic review of therapeutic drug monitoring (TDM) identifies three long-acting injectable (LAI) risperidone formulations. Areas covered: Limited data is available on two formulations (RBP-7000 and in Situ Microparticle), but 20 TDM articles on the microsphere formulation were found. Risperidone TDM includes the serum concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, used for calculating: 1) the risperidone/9-hydroxyrisperidone (R/9-OH-R) ratio (a measure of CYP2D6; values &gt;1 are indicative of a CYP2D6 poor metabolizer) and 2) the total risperidone concentration-to-dose (C/D) ratio (a measure of risperidone clearance with a normal value…

CYP2D6Therapeutic drug monitoring studiesAdministration OralPharmacologyMicrosphereInjections03 medical and health sciences0302 clinical medicineLong acting risperidonePaliperidone PalmitatemedicineAnimalsHumansPharmacology (medical)General Pharmacology Toxicology and Pharmaceutics610 Medicine &amp; healthActive metabolitePaliperidone PalmitateRisperidonemedicine.diagnostic_testbusiness.industryGeneral MedicineRisperidoneMicrospheres030227 psychiatryAntipsychotic agents/administration & dosage; delayed-action preparations; drug monitoring; injections; risperidone/administration & dosage; risperidone/blood; risperidone/metabolism; risperidone/pharmacokinetics; risperidone/pharmacology; risperidone/therapeutic use; schizophrenia/drug therapyTherapeutic drug monitoringDelayed-Action PreparationsDrug Monitoringbusiness030217 neurology & neurosurgerymedicine.drugAntipsychotic Agents
researchProduct